Evangelia Pardali
Overview
Explore the profile of Evangelia Pardali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poti F, Scalera E, Feuerborn R, Fischer J, Arndt L, Varga G, et al.
JCI Insight
. 2024 Nov;
9(24).
PMID: 39531328
Sphingosine 1-phosphate (S1P) is a lysosphingolipid with antiatherogenic properties, but mechanisms underlying its effects remain unclear. We here investigated atherosclerosis development in cholesterol-rich diet-fed LDL receptor-deficient mice with high or...
2.
Lesage A, Marceau F, Gibson C, Loenders B, Katzer W, Ambrosi H, et al.
Int Immunopharmacol
. 2022 Jan;
105:108523.
PMID: 35086057
PHA-022121 is a novel small molecule bradykinin B receptor antagonist, in clinical development for the treatment and prevention of hereditary angioedema attacks. The present study describes the in vitro pharmacological...
3.
Makowski L, Leffers M, Waltenberger J, Pardali E
J Cell Mol Med
. 2021 May;
25(11):5316-5325.
PMID: 33942489
Type 2 diabetes mellitus (T2DM) leads to monocyte dysfunction associated with atherogenesis and defective arteriogenesis. Transforming growth factor (TGF)-β1, placenta growth factor (PlGF)-1 and vascular endothelial growth factor (VEGF)A play...
4.
Kiefer K, Cremer S, Pardali E, Assmus B, Abou-El-Ardat K, Kirschbaum K, et al.
ESC Heart Fail
. 2021 Mar;
8(3):1873-1884.
PMID: 33779075
Aims: Somatic mutations in haematopoietic stem cells can lead to the clonal expansion of mutated blood cells, known as clonal haematopoiesis (CH). Mutations in the most prevalent driver genes DNMT3A...
5.
Pardali E, Dimmeler S, Zeiher A, Rieger M
Exp Hematol
. 2020 Jan;
83:95-104.
PMID: 31891750
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide. Many studies have provided evidence that both genetic and environmental factors induce atherosclerosis, leading thus to cardiovascular complications. Atherosclerosis is...
6.
Pardali E, Makowski L, Leffers M, Borgscheiper A, Waltenberger J
J Cell Mol Med
. 2018 Aug;
22(11):5429-5438.
PMID: 30102472
Type 2 diabetes mellitus (T2DM) is a cardiovascular risk factor which leads to atherosclerosis, an inflammatory disease characterized by the infiltration of mononuclear cells in the vessel. Bone morphogenetic protein...
7.
Tjaden K, Adam C, Godfrey R, Hanley P, Pardali E, Waltenberger J
Int J Cardiol
. 2018 Feb;
255:160-165.
PMID: 29425557
Background: Hypercholesterolemia (HC) is an important cardiovascular risk factor characterized by elevated low density lipoprotein-cholesterol (LDL-C) plasma levels. HC negatively affects monocyte function by reducing their chemotactic response towards different...
8.
Pardali E, Sanchez-Duffhues G, Gomez-Puerto M, Ten Dijke P
Int J Mol Sci
. 2017 Oct;
18(10).
PMID: 29039786
Fibrotic diseases are characterized by net accumulation of extracellular matrix proteins in affected organs leading to their dysfunction and ultimate failure. Myofibroblasts have been identified as the cells responsible for...
9.
Pardali E, Schmitz T, Borgscheiper A, Iking J, Stegger L, Waltenberger J
EJNMMI Res
. 2016 Oct;
6(1):77.
PMID: 27778311
Background: Circulating white blood cells crucially contribute to maintenance and repair of solid organs. Therefore, certain cell populations such as monocytes are attractive targets for use in molecular imaging and...
10.
Hawinkels L, Garcia de Vinuesa A, Paauwe M, Kruithof-de Julio M, Wiercinska E, Pardali E, et al.
Clin Cancer Res
. 2015 Sep;
22(1):96-106.
PMID: 26373572
Purpose: Antiangiogenic therapy, mostly targeting VEGF, has been applied in cancer patients for the last decade. However, resistance to anti-VEGF therapy and/or no significant benefit as monotherapeutic agent is often...